/ Press Release Details /

Active Pharmaceutical Ingredient Market Size Worth $243.8 Billion By 2025 | CAGR: 6.0%

The global active pharmaceutical ingredient market is expected to grow at growth rate of 6.0% to reach USD 243.8 billion by 2025.

The rise in the number of patents expiry, growing number of biological drugs in development, robust drug candidates in the pipeline, and increasing generic competition for achieving cost efficiency augmenting significant demand for the active pharmaceutical ingredient. In addition, key players are also securing long-term supply agreements to manufacture active pharmaceutical ingredients and new drug products. For which, these players are partnering with generic drug companies to grow the company’s extensive portfolio of generic API’s. For instance, In 2016 Pfizer aggressively acquired and partnered with Astra Zeneca, Watson Health, Medivation, Bamboo Therapeutics, Anacor, and Adaptive Biotechnologies in order to expand its product portfolio. Such facts would, in turn, establish a healthy platform for industry growth.

Key takeaways

In terms of manufacturer, the market is divided into captive and merchant. Captive segment captured more than 55% share of the global active pharmaceutical ingredient market.
Synthesis segment is categorized as synthetic and biologic. The synthetic segment accounted for a major chunk of the industry revenue throughout the study period.
Drug type category is divided into generic and branded. The generic segment is growing with the highest growth rate over the study period.
In terms of therapeutic area, the market is divided into Cardiovascular, Metabolic, CNS, Oncology, Musculoskeletal, NSAIDS, and others. Of these, the cardiovascular segment recorded USD 40.23 billion in 2016 and is anticipated to dominate the global market. Increasing incidences of cardiovascular disease have helped this segment to capture significant revenue share.
Companies namely Boehringer Ingelheim GmbH, Teva Pharmaceuticals. Pfizer, Inc, Novartis AG, Cambrex Corporation, Lonza Group, and Mylan N.V. are actively operating in this industry.
Teva Pharmaceuticals accounted for the highest revenue share of the global API market with more than 300 API products under the offering
Teva is exploring both organic as well as corporate development initiatives to achieve a leadership position in this industry, including the acquisition of Rimsa, a Mexico based leading pharmaceutical company in March 2016.

KEY BENEFITS OF THE REPORT:

Understanding of the strategies that are being adopted by the key players in this market to stay competitive
Extensive analysis of the key players dominating the competitive landscape of this market
In-depth analysis of the key factors are propelling the growth of the global market
Detailed analysis of the geographic region that will witness the strongest growth
Granular analysis of the current market scenario and the expected market grow

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation

MARKET, BY MANUFACTURER